ROCKAWAY, NJ, March 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Strategy Officer, Joshua Lev, will participate in a fireside chat at the 35th Annual Roth Conference in Dana Point, California during March 12-14, 2023.
Roth Conference
Date: Tuesday, March 14, 2023
Time: 1:00 PM PT
Event: Fireside Chat
electroCore will also be available for one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page here or email Investor Relations at This email address is being protected from spambots. You need JavaScript enabled to view it..
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Investors:
Rich Cockrell
CG Capital
404-736-3838
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.36 |
Daily Change: | 0.01 0.09 |
Daily Volume: | 44,130 |
Market Cap: | US$74.410M |
November 13, 2024 September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB